MX2019002097A - Antagonistas del receptor androgenico de tiohidantoina para el tratamiento del cancer. - Google Patents

Antagonistas del receptor androgenico de tiohidantoina para el tratamiento del cancer.

Info

Publication number
MX2019002097A
MX2019002097A MX2019002097A MX2019002097A MX2019002097A MX 2019002097 A MX2019002097 A MX 2019002097A MX 2019002097 A MX2019002097 A MX 2019002097A MX 2019002097 A MX2019002097 A MX 2019002097A MX 2019002097 A MX2019002097 A MX 2019002097A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
receptor antagonists
androgen receptor
subject
Prior art date
Application number
MX2019002097A
Other languages
English (en)
Spanish (es)
Inventor
C Bignan Gilles
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2019002097A publication Critical patent/MX2019002097A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019002097A 2016-08-22 2017-08-22 Antagonistas del receptor androgenico de tiohidantoina para el tratamiento del cancer. MX2019002097A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662377932P 2016-08-22 2016-08-22
PCT/IB2017/055063 WO2018037342A1 (en) 2016-08-22 2017-08-22 Thiohydantoin androgen receptor antagonists for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2019002097A true MX2019002097A (es) 2019-05-15

Family

ID=60009664

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002097A MX2019002097A (es) 2016-08-22 2017-08-22 Antagonistas del receptor androgenico de tiohidantoina para el tratamiento del cancer.

Country Status (12)

Country Link
US (1) US20190209539A1 (enExample)
EP (1) EP3500259A1 (enExample)
JP (1) JP2019528290A (enExample)
KR (1) KR20190040030A (enExample)
CN (1) CN109640986A (enExample)
AU (1) AU2017316756A1 (enExample)
BR (1) BR112019003406A2 (enExample)
CA (1) CA3034449A1 (enExample)
MA (1) MA45992A (enExample)
MX (1) MX2019002097A (enExample)
RU (1) RU2019108092A (enExample)
WO (1) WO2018037342A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019029521A1 (zh) * 2017-08-07 2019-02-14 正大天晴药业集团股份有限公司 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
SG11202108300VA (en) 2019-02-01 2021-08-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Crystal of diarylthiohydantoin compound
CN115403624B (zh) * 2022-09-30 2024-08-27 上海应用技术大学 一种二芳基硫代乙内酰脲化合物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3124481B1 (en) * 2010-02-16 2018-03-28 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP2911666B1 (en) * 2012-10-26 2022-08-24 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor

Also Published As

Publication number Publication date
AU2017316756A1 (en) 2019-02-21
BR112019003406A2 (pt) 2019-05-21
KR20190040030A (ko) 2019-04-16
CN109640986A (zh) 2019-04-16
RU2019108092A3 (enExample) 2020-11-30
US20190209539A1 (en) 2019-07-11
EP3500259A1 (en) 2019-06-26
WO2018037342A1 (en) 2018-03-01
MA45992A (fr) 2019-06-26
JP2019528290A (ja) 2019-10-10
RU2019108092A (ru) 2020-09-22
CA3034449A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
ZA202204929B (en) Rimegepant for cgrp related disorders
PH12013501341A1 (en) Morphinan compounds
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX393599B (es) Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
IN2015KN00414A (enExample)
MD20140059A2 (en) Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases
UA117830C2 (uk) Похідні біпіразолу як інгібітори jak
MX2015012006A (es) Inhibidores de bromodominio tetraciclicos.
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
EP2328414A4 (en) SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
NZ726366A (en) Syk inhibitors
MX2023010064A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
MY199091A (en) Therapeutic compounds
MY201535A (en) Therapeutic compounds
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
MX2015012741A (es) Palbociclib deuterado.
PH12021550671A1 (en) Prodrugs of cgrp antagonists
MX2019009586A (es) Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal.
BR112015026257A2 (pt) terapia de combinação compreendendo um composto di-hidropirazino-pirazina e um antagonista do receptor de andrógeno para tratar câncer de próstata
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
BR112019003406A2 (pt) antagonistas do receptor androgênico tio-hidantoína para o tratamento de câncer
NZ760627A (en) Novel treatment for hot flushes